As of November 24 at 5:35:34 PM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | 196.5M | 136.25M | 799.84M | 752.95M |
| Low Estimate | 195M | 108.5M | 795.59M | 726M |
| High Estimate | 198M | 164M | 805.32M | 788.4M |
| Year Ago Sales | 295.42M | 155.47M | 1.01B | 799.84M |
| Sales Growth (year/est) | -33.48% | -12.36% | -20.45% | -5.86% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 5G5.DE | -- | -- | -- | -- |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | Wedbush: Neutral to Neutral | 8/7/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 5/8/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 4/30/2024 |
| Downgrade | Wedbush: Outperform to Neutral | 2/8/2024 |
| Downgrade | Morgan Stanley: Equal-Weight to Underweight | 12/12/2023 |
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 11/8/2023 |